Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.41 |
| ▸ | FLT1 | P17948 | 5/20 | 0.41 |
| ▸ | FLT4 | P35916 | 5/20 | 0.41 |
| ▸ | KDR | P35968 | 5/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.39 |
| ▸ | QPCT | Q16769 | 6/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15405049 | 0.77 | AVPR2 (0.40) | KMT5AQPCTAVPR2AVPR1A | |
| SCHEMBL197798 | 0.76 | PDGFRB (0.46) | EGFRNCF1 | |
| SCHEMBL197931 | 0.75 | EGFR (0.40) | AXLEGFREHMT2NSD2 | |
| SCHEMBL199314 | 0.74 | EHMT2 (0.60) | EHMT2 | |
| SCHEMBL5224388 | 0.74 | EHMT2 (0.33) | EHMT2ENPP1 | |
| SCHEMBL199299 | 0.73 | EHMT2 (0.51) | EGFRFGFR1FLT1FLT4KDR | |
| SCHEMBL199128 | 0.71 | AXL (0.52) | AXLEGFRFGFR1FLT1FLT4 | |
| SCHEMBL9211831 | 0.71 | HTR4 (0.47) | EHMT2QPCTAVPR2AVPR1A | |
| Hydrochloric Acid SCHEMBL8509328 | 0.70 | KDR (0.43) | KMT5AAXLTYRO3MERTKEGFR | |
| SCHEMBL197702 | 0.70 | KDM4E (0.53) | FGFR1FLT1KDREHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827434-B1 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | claimed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-7652009-B2 | Substituted heterocycles and methods of use | AMGEM INC. (US) | 2010-01-26 | — | — | US | claimed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | claimed |
| EP-1881976-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Amgen Inc., (US) | 2008-01-30 | — | — | EP | claimed |
| EP-1827434-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | Amgen Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | claimed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2006060318-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC. (US) | 2006-06-08 | — | — | WO | claimed |
| EP-1827434-B1 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-1881976-B1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1881976-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Amgen Inc., (US) | 2008-01-30 | — | — | EP | disclosed |
| EP-1827434-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | Amgen Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060252777-A1 | Substituted heterocycles and methods of use | AMGEN INC. (US) | 2006-11-09 | — | — | US | disclosed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006060318-A2 | QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER | AMGEN INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | KMT5A 2388/4885AXL 776/4885TYRO3 484/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | KMT5A 1507/4885AXL 855/4885TYRO3 370/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | KMT5A 2388/4885AXL 776/4885TYRO3 484/4885 |
| US-20060252777-A1 | Substituted heterocycles and methods of use | HGF, HGFAC, MET | KMT5A 2795/4885AXL 578/4885TYRO3 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.